Medical Services

Myocardial infarction (MI), ischemic cardiomyopathy and congestive heart failure (CHF) remain among the most prominent health challenges worldwide, despite many breakthroughs in cardiovascular medicine. Moreover, despite advances in medical and surgical treatments, prognosis is poor with a median survival after onset of only 1.7 years in men and 3.2 years in women (American Heart Association, 2002). Currently no medication or procedure used clinically has shown efficacy in replacing myocardial scar with functioning contractile tissue.

Mesenchymal Stem Cells (MSCs) derived from bone marrow can be cloned and expanded in vitro about 1 million-fold and retain the ability to differentiate into several mesenchymal lineages. When compared with other cells types considered for cardiomyoplasty, MSCs appear to possess unique properties that may allow for convenient and highly effective cell therapy.

Clinical data has shown that the implantation of MNCs to MI patients was effective in promoting therapeutic angiogenesis. Apart from this, it is evident that co-transplantation of MSCs and MNCs may result in the enhancement of both cardiomiogenesis and angiogenesis.

CardioRel® is an autologous product designed for early or planned intervention in patients of MI providing mono-nuclear and mesenchymal stem cells for cardiac regeneration.